Rosiglitazone (ROS), a thiazolidinedione insulin sensitiser, could be used for the treatment of type 2 diabetes mellitus due to the enhanced sensitivity of peripheral tissue to insulin and improved utilisation of glucose through activating peroxisome proliferator‐activated receptor γ (Dawed et al. Here, INS is linked to type 2 diabetes mellitus.